A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo)

Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease

NCT00333788 ·Status: COMPLETED ·Phase: PHASE3

Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease

NCT00329550 ·Status: COMPLETED ·Phase: PHASE2

Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease

NCT00349752 ·Status: TERMINATED ·Phase: PHASE3

Examining the Long Term Safety, Efficacy, and Corticosteroid-sparing Effect of Certolizumab Pegol in Crohn's Disease

NCT00356408 ·Status: COMPLETED ·Phase: PHASE3

Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668)

NCT00329420 ·Status: COMPLETED ·Phase: PHASE2

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

NCT01190410 ·Status: COMPLETED ·Phase: PHASE2

Mucosal Healing Study in Crohn's Disease (CD)

NCT00297648 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease

NCT00552344 ·Status: COMPLETED ·Phase: PHASE3

Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab

NCT00308581 ·Status: COMPLETED ·Phase: PHASE3

Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease

NCT04151225 ·Status: WITHDRAWN ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

NCT00306215 ·Status: COMPLETED ·Phase: PHASE2

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy and Safety of NNC0114-0006 in Subjects With Active Crohn's Disease

NCT01751152 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

NCT00032799 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

NCT02405442 ·Status: TERMINATED ·Phase: PHASE2

Optimizing Cimzia in Crohn's Patients

NCT01024647 ·Status: UNKNOWN ·Phase: PHASE4

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

NCT02877134 ·Status: COMPLETED ·Phase: PHASE2

A Study to Investigate the Efficacy and Safety of GSK1605786A in the Treatment of Subjects With Moderately-to-Severely Active Crohn's Disease

NCT01277666 ·Status: COMPLETED ·Phase: PHASE3

A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease

NCT00615199 ·Status: COMPLETED ·Phase: PHASE2

Nine-Weeks Treatment With 683699 In Subjects With Moderately-To-Severely Active Crohn's Disease

NCT00101946 ·Status: COMPLETED ·Phase: PHASE2

Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease

NCT00102921 ·Status: COMPLETED ·Phase: PHASE2

Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.

NCT03234907 ·Status: COMPLETED ·Phase: PHASE3

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

NCT00032786 ·Status: COMPLETED ·Phase: PHASE3

A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy

NCT00771667 ·Status: COMPLETED ·Phase: PHASE2

Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas

NCT00354367 ·Status: WITHDRAWN ·Phase: PHASE3